Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619440 | 1.00 | GAA (0.59) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2135857 | 0.84 | GAA (0.42) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2619438 | 0.84 | GAA (0.42) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL30427258 | 0.82 | PARP10 (0.56) | NPC1KMT2A | |
| SCHEMBL14826991 | 0.81 | GAA (0.68) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2619439 | 0.80 | GAA (0.39) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2132208 | 0.80 | GAA (0.39) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2131864 | 0.80 | GAA (0.38) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2619442 | 0.80 | GAA (0.38) | GAARAB9AMAPTLMNATP53 | |
| SCHEMBL2619458 | 0.79 | GAA (0.40) | GAARAB9AMAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445892-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| WO-2010148650-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | GAA 2575/4885RAB9A 1337/4885MAPT 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.